In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CureVac N.V (NASDAQ: CVAC) closed the day trading at $2.75 down -6.78% from the previous closing price of $2.95. In other words, the price has decreased by -$6.78 from its previous closing price. On the day, 0.69 million shares were traded. CVAC stock price reached its highest trading level at $2.9127 during the session, while it also had its lowest trading level at $2.7292.
Ratios:
For a better understanding of CVAC, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.00 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.45. For the most recent quarter (mrq), Quick Ratio is recorded 6.19 and its Current Ratio is at 6.20. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on April 25, 2024, Downgraded its rating to Market Perform and sets its target price to $4 from $12 previously.
On June 08, 2023, SVB Securities started tracking the stock assigning a Outperform rating and target price of $13.
UBS Upgraded its Neutral to Buy on January 19, 2023, whereas the target price for the stock was revised from $8 to $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 27 ’24 when Pierre Kemula bought 55 shares for $3.08 per share.
Pierre Kemula bought 34,000 shares of CVAC for $105,400 on Sep 25 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 616929472 and an Enterprise Value of 453383520. As of this moment, CureVac’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.06. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.04 while its Price-to-Book (P/B) ratio in mrq is 0.76. Its current Enterprise Value per Revenue stands at 6.884 whereas that against EBITDA is -1.677.
Stock Price History:
Over the past 52 weeks, CVAC has reached a high of $6.24, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is -3.26%, while the 200-Day Moving Average is calculated to be -12.85%.
Shares Statistics:
Over the past 3-months, CVAC traded about 485.83K shares per day on average, while over the past 10 days, CVAC traded about 568580 shares per day. A total of 224.34M shares are outstanding, with a floating share count of 93.63M. Insiders hold about 58.26% of the company’s shares, while institutions hold 5.18% stake in the company. Shares short for CVAC as of 1732838400 were 4210816 with a Short Ratio of 8.67, compared to 1730332800 on 4560158. Therefore, it implies a Short% of Shares Outstanding of 4210816 and a Short% of Float of 10.5.
